2型糖尿病透析依赖急性肾损伤后早期启用SGLT-2抑制剂
该研究采用目标试验模拟设计,利用TriNetX电子健康记录,纳入2型糖尿病透析依赖急性肾损伤、出院后停止透析且既往一年无SGLT-2抑制剂处方的成人。比较出院后30天内 vs 31-90天首次处方SGLT-2抑制剂,经1:1倾向评分匹配后每组1912例。主要终点不良肾脏事件在早期组74例(3.9%)vs 晚期组119例(6.2%),AHR 0.62(95%CI 0.46-0.83);全因死亡和MACE无显著差异,6个月安全性结局相似。结论支持AKI恢复期及时启用SGLT-2抑制剂。
要点
- 2型糖尿病AKI-D出院后30天内启用SGLT-2抑制剂,不良肾脏事件AHR 0.62(95%CI 0.46-0.83),优于31-90天启用。
- 6个月记录的安全性结局在早期与晚期启用组间相似。
- 适用人群为2型糖尿病、因AKI-D住院、出院后已停止透析、既往一年无SGLT-2抑制剂处方的成人。
- 该研究为观察性队列的目标试验模拟,结论需前瞻性随机临床试验验证。
适用人群与场景
- 成人2型糖尿病患者,因透析依赖急性肾损伤住院,出院后已停止透析,且既往一年内无SGLT-2抑制剂处方。
- 研究场景为出院后门诊处方启动,非急诊或ICU床旁急性期用药。
诊断标准与关键阈值
- 不良肾脏事件定义:重新启动透析、新发终末期肾病、或记录的eGFR小于15 mL/min/1.73 m2。
- 早期启用定义:出院后30天内首次记录SGLT-2抑制剂处方;晚期启用定义:出院后31至90天内首次处方。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:基于TriNetX全球协作网络电子健康记录(2015年1月1日至2024年9月1日)的队列研究,采用目标试验模拟设计。
- 样本量与中心数:倾向评分匹配前4406例 eligible 患者,匹配后每组1912例;中心数原文未提及。
- 人群:2型糖尿病、因AKI-D住院、出院后停止透析、既往一年无SGLT-2抑制剂处方的成人;早期组平均年龄63.0岁,男性57.6%;晚期组平均年龄62.8岁,男性58.2%。
- 干预与对照:出院后30天内首次处方SGLT-2抑制剂 vs 出院后31至90天内首次处方。
- 主要终点:不良肾脏事件早期组74例(3.9%)vs 晚期组119例(6.2%),AHR 0.62(95%CI 0.46-0.83)。
- 随访:平均3.4年(IQR 1.1-3.3年)。
证据类型、等级与局限
- 证据类型:观察性队列研究,采用目标试验模拟设计、90天landmark设计和1:1倾向评分匹配。
- 证据等级或推荐强度:原文未提及。
- 局限:观察性设计存在残余混杂可能;基于电子健康记录,结局依赖记录准确性;原文未提及中心数;结论需前瞻性随机临床试验验证。
对床旁实践的改变
- 对于2型糖尿病AKI-D出院后已停止透析且既往未用SGLT-2抑制剂的患者,可考虑在出院后30天内启动SGLT-2抑制剂以降低不良肾脏事件风险。
- 该证据不改变急诊或ICU急性期决策;启动时机为出院后恢复期门诊场景。
- 早期启用未显示死亡或心血管事件获益,也未见6个月记录的安全性结局差异,决策时需结合患者具体情况。
- 该研究为观察性目标试验模拟,不能等同于随机对照试验的推荐强度。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve kidney and cardiovascular outcomes in type 2 diabetes, chronic kidney disease, and heart failure, but optimal initiation timing after dialysis-requiring acute kidney injury (AKI-D) is uncertain.
OBJECTIVE: To compare outcomes associated with SGLT-2 inhibitor prescription within 30 days vs 31 to 90 days after discharge among adults with type 2 diabetes recovering from AKI-D.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study using a target trial emulation design used TriNetX Global Collaborative Network electronic health records from January 1, 2015, to September 1, 2024. Eligible adults had type 2 diabetes, were hospitalized for AKI-D, had dialysis discontinued after discharge, and had no SGLT-2 inhibitor prescription in the prior year.
EXPOSURE: First documented SGLT-2 inhibitor prescription within 30 days after discharge vs 31 to 90 days after discharge.
MAIN OUTCOMES AND MEASURES: Primary outcomes were adverse kidney events, all-cause mortality, and major adverse cardiovascular events. Adverse kidney events included dialysis reinitiation, incident end-stage kidney disease, or recorded estimated glomerular filtration rate less than 15 mL/min/1.73 m2. Selected 6-month safety outcomes were also assessed. A 90-day landmark design and 1:1 propensity score matching were used.
RESULTS: Among 4406 eligible patients before propensity score matching, 2268 initiated SGLT-2 inhibitors within 30 days (mean [SD] age, 63.5 [12.9] years; 1336 male [58.9%]), and 2138 initiated SGLT-2 inhibitors between 31 and 90 days (mean [SD] age, 62.7 [13.5] years; 1210 male [56.6%]). After 1:1 propensity score matching, 1912 patients remained in each group (mean [SD] age, 63.0 [13.0] vs 62.8 [13.5] years; 1102 [57.6%] vs 1112 [58.2%] male, in the early vs late SGLT-2 initiation groups, respectively). During a mean follow-up of 3.4 years (IQR, 1.1-3.3 years), early prescription was associated with a lower risk of adverse kidney events compared with late prescription in 74 patients (3.9%) vs 119 patients (6.2%) (adjusted hazard ratio [AHR], 0.62; 95% CI, 0.46-0.83). All-cause mortality (AHR, 1.06; 95% CI, 0.84-1.35; P = .63) and major adverse cardiovascular events (AHR, 1.03; 95% CI, 0.80-1.34; P = .81) did not differ significantly. Recorded 6-month safety outcomes were also similar.
CONCLUSIONS AND RELEVANCE: In adults with type 2 diabetes recovering from AKI-D, SGLT-2 inhibitor prescription within 30 days after discharge was associated with fewer adverse kidney events than prescription at 31 to 90 days, without significant differences in mortality, cardiovascular events, or recorded short-term safety outcomes. These findings support timely initiation of SGLT-2 inhibitors during the post-AKI recovery period and provide a rationale for prospective randomized clinical trials.
参考来源
- Chou YT, Chen JY, Jiang ZH, et al. Early Sodium-Glucose Cotransporter-2 Inhibitor Use After Acute Kidney Injury in Type 2 Diabetes. JAMA Netw Open. 2026. PMID: 42658493. doi:10.1001/jamanetworkopen.2026.31231
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。